98%
921
2 minutes
20
Background: The proneural-to-mesenchymal transition (PMT) represents a crucial phenotypic transformation in glioblastoma. Glioma-associated mesenchymal stromal/stem cells (GaMSCs) play a significant role in diverse biological processes of gliomas. However, the impact of exosomes released from GaMSCs (GaMSCs-Exos) on the PMT of glioblastoma remains inadequately understood. This study aimed to explore the effects and mechanisms of GaMSCs-derived exosomal miRNA-191-5p on the PMT of glioblastoma.
Methods And Results: Conditioned medium from three independently established GaMSCs lines (GaMSCs-CM) significantly enhanced the tumorigenicity of glioma cells. Further analysis demonstrated that GaMSC-Exos, isolated from GaMSCs-CM, promoted both the tumorigenicity and PMT of glioma cells, both in vitro and in vivo. Exosomal miR-191-5p derived from GaMSCs was identified as the principal mediator. Overexpression and inhibition of miR-191-5p affected the tumorigenicity and PMT of glioma cells, in both laboratory and animal models. Bioinformatics analyses and luciferase reporter assays confirmed that miR-191-5p targets PTEN. Additionally, rescue experiments indicated that increased PTEN expression could reverse the effects of miR-191-5p overexpression on tumorigenicity and PMT through modulation of the PI3K/AKT signaling pathway.
Conclusion: Our findings highlight the role of GaMSC-Exos in mediating the intercellular transfer of miRNA-191-5p, which facilitates the PMT of glioma. The process underlying the enhanced aggressiveness and PMT is driven by miR-191-5p, promoting glioma progression by targeting PTEN and activating the PI3K/AKT signaling pathway.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12248735 | PMC |
http://dx.doi.org/10.2147/IJN.S515771 | DOI Listing |
J Neurooncol
September 2025
Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Purpose: Glioblastoma (GBM) remains one of the most aggressive primary brain tumors with poor survival outcomes and a lack of approved therapies. A promising novel approach for GBM is the application of photodynamic therapy (PDT), a localized, light-activated treatment using tumor-selective photosensitizers. This narrative review describes the mechanisms, delivery systems, photosensitizers, and available evidence regarding the potential of PDT as a novel therapeutic approach for GBM.
View Article and Find Full Text PDFNeurol Res
September 2025
Henan Provincial People's Hospital, Department of Surgery of Spine and Spinal Cord, People's Hospital of Zhengzhou University, Zhengzhou, China.
Background: Immunotherapy holds significant yet underexplored potential for low-grade glioma (LGG) treatment. We therefore interrogated the role of Fanconi Anemia Complementation Group C (FANCC) as a novel immune checkpoint regulator given its spatial correlation with tumor microenvironments and clinical associations with immunosuppressive markers.
Objectives: FANCC is implicated in various tumor progressions; its role in LGG remains unexplored.
JCI Insight
September 2025
The Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children; Toronto, Canada.
More than a third of patients with glioblastoma experience tumor progression during adjuvant therapy. In this study, we performed a high-throughput drug repurposing screen of FDA-approved agents capable of crossing the blood-brain barrier in order to find agents to counteract acquired or inherent glioma cell resistance to temozolomide-associated cytotoxicity. We identified the cholesterol processing inhibitor, lomitapide, as a potential chemosensitizer in glioblastoma.
View Article and Find Full Text PDFBrain Behav
September 2025
Department of Neurosurgery, First Medical Center of the Chinese PLA General Hospital, Beijing, People's Republic of China.
Background: The gut microbiota plays a crucial role in the development of glioma. With the evolution of artificial intelligence technology, applying AI to analyze the vast amount of data from the gut microbiome indicates the potential that artificial intelligence and computational biology hold in transforming medical diagnostics and personalized medicine.
Methods: We conducted metagenomic sequencing on stool samples from 42 patients diagnosed with glioma after operation and 30 non-intracranial tumor patients and developed a Gradient Boosting Machine (GBM) machine learning model to predict the glioma patients based on the gut microbiome data.
Mol Biol Rep
September 2025
Dr. B. R. Ambedkar Centre for Biomedical Research North Campus , University of Delhi, 110007, Delhi, India.
Background: Standard treatment for glioblastoma includes chemotherapy, alkylating agents such as temozolomide (TMZ); however, MGMT resistance leads to recurrence. Demethoxycurcumin (DMC) has been reported to inhibit cancer cell growth, induce apoptosis, and prevent metastasis in different cancer models. We investigated the DMC-induced apoptosis and autophagy via inhibition of the AKT/mTOR pathway in human glioma U87MG and T98G cell lines.
View Article and Find Full Text PDF